Cancer Immunotherapy, Part 3: Challenges and Future Trends
- PMID: 28781505
- PMCID: PMC5521300
Cancer Immunotherapy, Part 3: Challenges and Future Trends
Abstract
Despite dramatic breakthroughs, obstacles remain for the field of immunotherapy in cancer. These include the inability to predict treatment efficacy and patient response; the need for improved biomarkers; the development of resistance to immunotherapies; the lack of optimized clinical study designs; and high costs. Are solutions in sight?
Figures
References
-
- Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immuno therapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12(5):631–645. - PubMed
-
- Chiriva-Internati M, Bot A. A new era in cancer immunotherapy: discovering novel targets and reprogramming the immune system. Int Rev Immunol. 2015;34(2):101–103. - PubMed
-
- Zugazagoitia J, Guedes C, Ponce S, et al. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551–1566. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources